Fuyang Niweisaier Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Fuyang Niweisaier Technology Co., Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include NX NIVUXEL. The owner is based in Fuyang.
Room 104, Bldg 1, Shuian Mingzhu
777 Hongxing Rd, Zhoupeng Office, Yingquan
Fuyang 236000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Fuyang Niweisaier Technology Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Fuyang Niweisaier Technology Co., Ltd. have?
Fuyang Niweisaier Technology Co., Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.
What trademark classes does Fuyang Niweisaier Technology Co., Ltd. file in?
Fuyang Niweisaier Technology Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Fuyang Niweisaier Technology Co., Ltd.'s most well-known trademarks?
Fuyang Niweisaier Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as NX NIVUXEL. These are among 1 currently registered trademark in the portfolio.
What is Fuyang Niweisaier Technology Co., Ltd.'s trademark registration success rate?
Fuyang Niweisaier Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.